drugset
drugset / Trial / NCT06629584

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

NCT06629584 ↗

Phase 2 Recruiting 40 enrolled M.D. Anderson Cancer Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.

Timeline

Start
2025-02-14
Primary completion
2026-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Asciminib Unknown 80 mg Oral

Indications

cancer